Lantheus Medical Imaging is touting data from a study of its investigational flurpiridaz F-18 radiotracer for myocardial perfusion imaging (MPI). The results will be presented at the American Heart Association (AHA) conference taking place November 7-11 in Orlando, FL.
The data are from a multicenter phase III study being performed in the U.S., Canada, and Finland. The trial is designed to evaluate the efficacy of flurpiridaz F-18 PET MPI versus SPECT MPI for detecting significant coronary artery disease, Lantheus said.
Approximately 800 patients with known or suspected coronary artery disease who were either scheduled for or had completed invasive coronary angiography (without intervention) were enrolled in the trial. The subset analysis focused on the female subpopulation.
Flurpiridaz F-18 demonstrated improved coronary artery disease detection and reduced radiation exposure in women, compared with standard SPECT MPI, according to Lantheus.
